Work Area: Valuation

Latest content

Beware the flow of money into China’s transactions space

Saturday Opinion: Encouraging patent deals and lending through metrics and incentives could lay a trap for those who want a higher-quality patent system

03 April 2021

BlackBerry CEO: Majority of cash for patent portfolio expected in upfront payment

After IAM broke news of possible sale last year Canadian tech giant has confirmed it is in exclusive negotiations with a “North American” bidder for a part of its 38,000 asset stockpile

01 April 2021

IP analytics unicorn emerges with Softbank, Tencent backing

Singapore-based PatSnap says its latest round of fundraising pushed its valuation north of $1 billion

19 March 2021

Japanese government to weigh SEP licensing questions again

New group includes big names from the corporate IP world, representing Japanese stakeholders from both the auto and the electronics industries

17 March 2021

What life sciences businesses need to know about data commercialisation

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research

25 February 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions

18 February 2021

How an army of armchair investors showed why BlackBerry is seeking buyers for its 38,000 patents

The Canadian tech giant has built a licensing operation that brings in more than $300 million annually, but those gains have failed to shift shareholder sentiment

17 February 2021

Elite patent-owning companies enjoy three year run of stock success, new research reveals

A composite index of publicly-quoted entities with largest US portfolios has enjoyed strong performance since 2018

15 February 2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

A major milestone in the medical cannabinoid patent market has been passed

09 February 2021

The Roivant Sciences dealmaking strategy revolutionising life sciences IP monetisation

A deep dive into the trail-blazing biopharma business established by former hedge fund partner Vivek Ramaswamy

02 February 2021

Unlock unlimited access to all IAM content